ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has earned an average recommendation of “Hold” from the six research firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $12.58.

Several analysts have commented on the stock. ValuEngine raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Monday, August 28th. BidaskClub raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. HC Wainwright reissued a “buy” rating and set a $9.50 price target on shares of ZIOPHARM Oncology in a research report on Tuesday, November 7th. Finally, Zacks Investment Research raised shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research report on Friday, November 10th.

Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) opened at $4.36 on Tuesday. ZIOPHARM Oncology has a 1 year low of $4.03 and a 1 year high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.13) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13). The firm had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $1.66 million. The business’s quarterly revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.11) earnings per share. equities research analysts forecast that ZIOPHARM Oncology will post -0.54 earnings per share for the current year.

In related news, CEO Laurence James Neil Cooper acquired 6,440 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The stock was purchased at an average cost of $4.68 per share, with a total value of $30,139.20. Following the transaction, the chief executive officer now directly owns 1,083,731 shares of the company’s stock, valued at approximately $5,071,861.08. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 10.40% of the company’s stock.

Several institutional investors have recently made changes to their positions in ZIOP. Chevy Chase Trust Holdings Inc. purchased a new position in shares of ZIOPHARM Oncology in the 3rd quarter valued at approximately $104,000. Amalgamated Bank raised its position in shares of ZIOPHARM Oncology by 12.9% in the 2nd quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 1,924 shares during the last quarter. Oppenheimer & Co. Inc. raised its position in shares of ZIOPHARM Oncology by 50.0% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 6,000 shares during the last quarter. BB&T Securities LLC purchased a new position in shares of ZIOPHARM Oncology in the 2nd quarter valued at approximately $112,000. Finally, Adell Harriman & Carpenter Inc. purchased a new position in shares of ZIOPHARM Oncology in the 3rd quarter valued at approximately $141,000. 40.25% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “ZIOPHARM Oncology Inc. (ZIOP) Given Consensus Recommendation of “Hold” by Brokerages” was first published by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/05/ziopharm-oncology-inc-ziop-given-consensus-recommendation-of-hold-by-brokerages.html.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Receive News & Ratings for ZIOPHARM Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.